Introducing CiiTA’s Free Duplicate Discount Risk Assessment

At present most manufacturers are not actively or effectively managing their exposure to 340B duplicate discounts. Current projections of the scope of the issue are severely limited by a lack of data, and many manufacturers are completely unaware of the significance of the problem. Additionally, the data required to identify duplicate claims is difficult to acquire. No single party has sufficient data to analyze 340B duplicate discounts. Medicaid data must be solicited from each individual state Medicaid office, and the availability and formatting of that data is inconsistent.

To address this gap, CiiTA, LLC is offering pharmaceutical manufacturers a CiiTA-Duplicate-Discount-Risk-Assesment free of charge for a single state as an introduction to CiiTA’s 340B portfolio. The assessment utilizes CiiTA’s proprietary data model to analyze PHS 340B Drug Discount Program usage patterns and assess duplicate discount risk to a specific manufacturer. This allows manufacturers to evaluate 340B duplicate discount exposure and identify high-risk covered entities for in-depth review.

For more information, please contact:

Jason Hardaway
Managing Partner
503.757.6564
jhardaway@ciitainc.com